Nervous System

Narcolepsy and cataplexy

Clinical Overview and When to Suspect Narcolepsy

Narcolepsy is a chronic disorder of central hypersomnolence caused by loss of hypothalamic hypocretin (orexin)-producing neurons (Type 1) or by an unclear mechanism with preserved hypocretin (Type 2).

— Excessive daytime sleepiness (EDS) persisting ≥3 months

— Sleep attacks: sudden, irresistible episodes of falling asleep in inappropriate situations

— Cataplexy: sudden bilateral loss of muscle tone triggered by strong emotions (pathognomonic for Type 1)

— Disrupted nocturnal sleep, hypnagogic/hypnopompic hallucinations, sleep paralysis

Board pearl: Narcolepsy Type 1 (with cataplexy) = low CSF hypocretin-1 (orexin-A) ≤110 pg/mL and is strongly associated with HLA-DQB1*06:02. Type 2 lacks cataplexy and has normal hypocretin levels.

Classic patient: adolescent or young adult (onset 10–30 years) with irresistible daytime sleepiness despite adequate nighttime sleep

Suspect narcolepsy when:

Presentation Patterns and Key History Findings

The pentad of narcolepsy (not all features required):

Additional history clues:

— Automatic behaviors (writing gibberish, driving to wrong location)

— Fragmented nocturnal sleep (paradoxically)

— Weight gain — loss of orexin → ↓ energy expenditure

— Childhood onset may mimic ADHD or behavioral disorders

Next best step: Detailed sleep history + sleep diary/actigraphy for ≥1–2 weeks before formal testing to ensure adequate habitual sleep and exclude insufficient sleep syndrome.

Excessive daytime sleepiness — most universal and often most disabling symptom; short naps are refreshing

Cataplexy — sudden jaw drop, head nod, knee buckling, or full postural collapse; consciousness preserved; triggered by laughter, surprise, anger

Hypnagogic hallucinations — vivid visual/auditory hallucinations at sleep onset

Hypnopompic hallucinations — similar hallucinations upon awakening

Sleep paralysis — transient inability to move or speak during sleep–wake transitions

Physical Exam and Bedside Assessment

— Bilateral loss of muscle tone (face, jaw, neck, limbs)

— Preserved consciousness — patient can recall the event

— No postictal state (distinguishes from seizure)

— Reflexes are absent/↓ during the attack (hypotonia)

— Episodes last seconds to a few minutes

— Papilledema, cranial nerve deficits → hypothalamic/brainstem lesion

— Systemic disease: sarcoidosis, MS, anti-NMDA receptor encephalitis

Key distinction: Cataplexy vs syncope — cataplexy is emotionally triggered, consciousness is preserved, there is no loss of pulse or pallor, and recovery is immediate. Syncope involves loss of consciousness and often hemodynamic compromise.

Key distinction: Cataplexy vs atonic seizures — cataplexy has emotional trigger, preserved consciousness, no EEG epileptiform correlate.

General exam is typically normal between episodes

During cataplexy:

Neurologic exam between episodes: normal

Assess BMI — obesity common due to hypocretin deficiency

Look for signs suggesting secondary causes:

Diagnostic Workup — Sleep Studies

Diagnosis requires objective testing after ≥1–2 weeks of adequate sleep (confirmed by sleep diary/actigraphy) and discontinuation of REM-suppressing medications (SSRIs, SNRIs, TCAs) for ≥2 weeks.

Step 1: Overnight polysomnography (PSG)

Step 2: Multiple Sleep Latency Test (MSLT) — performed the morning after PSG

— Mean sleep latency ≤8 minutes AND

— ≥2 SOREMPs (a SOREMP on the preceding PSG counts as one)

Board pearl: A SOREMP = REM sleep occurring within 15 minutes of sleep onset. Normal individuals do not enter REM for ~90 minutes. SOREMPs reflect the intrusion of REM phenomena (dreams, atonia) into wakefulness — this underlies cataplexy, sleep paralysis, and hallucinations.

Rules out other sleep disorders (OSA, periodic limb movements)

Often shows short sleep latency and sleep-onset REM period (SOREMP)

5 nap opportunities at 2-hour intervals

Diagnostic criteria for narcolepsy:

Diagnostic Workup — CSF Hypocretin and HLA Typing

— ≤110 pg/mL (or <1/3 of normal mean) is diagnostic of Narcolepsy Type 1 even without MSLT

— Useful when cataplexy is atypical or MSLT is equivocal

— Not required if cataplexy is unambiguous + MSLT is positive

— Present in >98% of Type 1 narcolepsy

— However, also present in ~25% of general population → high sensitivity but LOW specificity

— Useful for: negative result essentially excludes Type 1

— NOT sufficient alone for diagnosis

Narcolepsy Type 1 diagnostic criteria:

— EDS ≥3 months + definite cataplexy + positive MSLT (or low CSF hypocretin-1)

Narcolepsy Type 2 diagnostic criteria:

— EDS ≥3 months, no cataplexy, positive MSLT, normal or unknown CSF hypocretin-1

Next best step: If a patient has clear-cut cataplexy + EDS → PSG/MSLT confirms. If cataplexy is questionable → CSF hypocretin-1 can clinch the diagnosis.

CSF hypocretin-1 (orexin-A) measurement:

HLA-DQB1*06:02:

First-Line Management of Excessive Daytime Sleepiness

Non-pharmacologic (adjunctive, always recommended):

Pharmacotherapy for EDS:

— Mechanism: promotes wakefulness (exact mechanism unclear; ↑ dopamine, histamine)

— Well tolerated; lower abuse potential than traditional stimulants

— Side effects: headache, nausea, insomnia, ↓ efficacy of oral contraceptives (CYP3A4 inducer)

— Taken at bedtime + again 2.5–4 h later

— Uniquely improves EDS AND cataplexy AND nocturnal sleep consolidation

— Side effects: nausea, enuresis, confusion, respiratory depression

— DEA Schedule III; REMS program required (high abuse potential)

Board pearl: Modafinil treats EDS but NOT cataplexy. Sodium oxybate treats both.

Scheduled short naps (15–20 min, 1–2×/day) — often dramatically refreshing

Regular sleep–wake schedule; adequate nocturnal sleep (7–9 h)

Sleep hygiene, avoid alcohol and sedatives

Driving safety counseling

First-line: Modafinil or armodafinil

Alternative/add-on: Sodium oxybate (gamma-hydroxybutyrate)

Management of Cataplexy

Cataplexy results from inappropriate intrusion of REM-associated atonia into wakefulness → treatment targets REM suppression or stabilization.

— Most effective; reduces cataplexy frequency by >60–90%

— Also consolidates sleep and ↓ EDS

— Venlafaxine (SNRI) — commonly used; ↑ norepinephrine/serotonin → suppresses REM

— Other SNRIs or SSRIs (fluoxetine)

— TCAs (clomipramine, protriptyline) — effective but more side effects

— Abrupt withdrawal of these agents can cause rebound cataplexy (status cataplecticus)

— Approved for EDS and cataplexy

— Non-scheduled (no abuse potential)

— QTc prolongation risk

Next best step: Patient with narcolepsy Type 1 needing treatment for both EDS and cataplexy → sodium oxybate (addresses both) OR modafinil (for EDS) + venlafaxine (for cataplexy).

First-line for cataplexy: Sodium oxybate (oxybate salts)

Alternatives — REM-suppressing agents:

Newer agent: Pitolisant — histamine H3 receptor inverse agonist

Treatment Algorithms and Refractory Cases

Stepwise approach:

1. All patients: sleep hygiene + scheduled naps + driving counseling

2. EDS alone (Type 2 or mild Type 1): modafinil/armodafinil

3. EDS + cataplexy: sodium oxybate (preferred) OR modafinil + SNRI

4. Refractory EDS: add methylphenidate or dextroamphetamine (traditional stimulants)

— Higher abuse potential; scheduled substances

— Monitor HR, BP, weight

5. Solriamfetol (dopamine/NE reuptake inhibitor) — newer option for refractory EDS

— Dose-dependent ↑ BP, insomnia

Refractory cataplexy:

— ↑ sodium oxybate dose

— Combine sodium oxybate + SNRI

— Avoid abrupt withdrawal of anticataplectic agents

Board pearl: Traditional stimulants (amphetamines, methylphenidate) are second-line for EDS due to abuse potential and cardiovascular side effects. Modafinil is preferred first because of a better safety profile.

Key distinction: Stimulants help EDS but do NOT treat cataplexy. Only sodium oxybate, SNRIs/SSRIs/TCAs, and pitolisant target cataplexy.

Special Populations — Pediatric Narcolepsy

— Cataplexy can present as "cataplectic facies" — persistent hypotonic facial expression, tongue protrusion, jaw weakness

— May be misdiagnosed as ADHD, epilepsy, depression, or behavioral disorder

— Rapid weight gain near onset is characteristic

— Modafinil first-line for EDS (used off-label in children)

— Sodium oxybate approved for age ≥7 for both EDS and cataplexy

— School accommodations: scheduled naps, extended test time, counseling

Board pearl: A child with sudden-onset excessive sleepiness + rapid weight gain + facial hypotonia → think narcolepsy Type 1. Check CSF hypocretin-1 if MSLT is inconclusive.

Onset commonly in childhood/adolescence (peak ~14 years)

Presentation may differ:

Diagnosis: same criteria (PSG + MSLT); CSF hypocretin especially useful in children who cannot comply with MSLT

Treatment:

Special Populations — Pregnancy, Elderly, and Comorbidities

Pregnancy:

Elderly:

Comorbidities:

Board pearl: Obstructive sleep apnea must be excluded or treated before attributing EDS to narcolepsy.

Most narcolepsy medications lack adequate safety data

Modafinil — potential teratogen (cleft lip/palate in animal studies) → avoid

Sodium oxybate — limited data → generally discontinued

Stimulants — associated with preterm birth, growth restriction → avoid if possible

Management: maximize non-pharmacologic strategies (scheduled naps, sleep optimization)

Cataplexy may ↓ during pregnancy in some patients

New-onset severe hypersomnolence in older adults → consider secondary causes (hypothalamic lesion, neurodegenerative disease) before diagnosing narcolepsy

Use lower doses of stimulants; monitor cardiovascular parameters

Sodium oxybate — use cautiously with renal impairment, concurrent sedatives

Depression/anxiety — common comorbidities; SSRIs/SNRIs can serve dual purpose

OSA — must be treated adequately before MSLT; can coexist

↑ BMI — counsel on weight management; orexin loss promotes weight gain

Complications and Emergencies

— Sleep attacks while driving → motor vehicle accidents

— Falls during cataplectic episodes

— All narcolepsy patients must receive driving safety counseling

— Prolonged, sub-continuous cataplexy lasting hours

— Usually triggered by abrupt withdrawal of anticataplectic medications (SNRIs, TCAs)

— Management: reinstate the withdrawn medication; supportive care

— Depression, anxiety (up to 30–50%)

— Social stigma, academic/occupational impairment

— Relationship difficulties

— Sodium oxybate: respiratory depression (especially with opioids, alcohol, benzodiazepines), Na⁺ load (contains significant sodium → caution in HF, HTN)

— Stimulants: tachycardia, HTN, insomnia, dependence

— SNRIs/TCAs: serotonin syndrome risk if combined

Next best step: When discontinuing anticataplectic therapy → taper gradually to prevent rebound cataplexy/status cataplecticus.

Accidental injury:

Status cataplecticus:

Psychosocial complications:

Medication complications:

When to Escalate Care and Refer

— All patients with suspected narcolepsy for confirmatory PSG/MSLT

— Atypical presentations (late onset, no cataplexy, equivocal MSLT)

— Refractory EDS or cataplexy despite adequate pharmacotherapy

— Need for CSF hypocretin-1 testing

— Concern for structural hypothalamic lesion (secondary narcolepsy)

— Associated neurologic deficits on exam

— Consideration of anti-NMDA receptor encephalitis, MS, sarcoidosis

— Status cataplecticus

— Severe medication side effects (respiratory depression from sodium oxybate)

— Suicidal ideation from comorbid depression

— Psychiatry/psychology for comorbid mood disorders

— Occupational rehabilitation for workplace accommodations

— Social work for disability applications

Board pearl: MRI brain (focused on hypothalamus/brainstem) should be obtained in atypical narcolepsy — late onset, rapidly progressive, or neurologic signs — to rule out secondary causes.

Refer to sleep medicine specialist:

Refer to neurology if:

Consider inpatient management:

Multidisciplinary care:

Key Differentials — Distinguishing Narcolepsy from Other Causes of EDS

— Most common cause of EDS; patient simply does not sleep enough

— History: <7 h/night; resolves with extended sleep

— MSLT may show short latency but no SOREMPs

— Snoring, witnessed apneas, obesity, ↑ neck circumference

— PSG shows AHI ≥5 with symptoms; no SOREMPs on MSLT (usually)

— Treat OSA first; if EDS persists → consider coexisting narcolepsy

— EDS + prolonged unrefreshing naps (unlike narcolepsy's refreshing naps)

— ↑ total sleep time (>11 h/24 h), severe sleep inertia ("sleep drunkenness")

— MSLT: mean sleep latency ≤8 min but <2 SOREMPs

— Recurrent episodes of hypersomnia + hyperphagia + hypersexuality + cognitive/behavioral changes

— Episodic; normal between episodes

— Predominantly adolescent males

Key distinction: Refreshing naps point toward narcolepsy; unrefreshing prolonged sleep favors idiopathic hypersomnia.

Insufficient sleep syndrome:

Obstructive sleep apnea (OSA):

Idiopathic hypersomnia:

Kleine-Levin syndrome:

Key Differentials — Distinguishing Cataplexy from Mimics

— No emotional trigger; loss of consciousness; postictal state

— EEG shows epileptiform discharges

— Loss of consciousness + hemodynamic changes (pallor, ↓ BP/HR)

— Positional triggers (standing), not emotional

— Variable presentation; may mimic cataplexy

— Typically longer duration, less stereotyped

— Normal EEG, no SOREMPs on MSLT

— Focal neurologic deficits; typically older patient with vascular risk factors

— No emotional trigger

— Episodes of weakness lasting hours; triggered by meals, exercise, or rest

— Check K⁺ during attack; EMG findings

Board pearl: Cataplexy is virtually pathognomonic for narcolepsy Type 1. A clear history of emotionally triggered bilateral muscle weakness with preserved consciousness + rapid recovery requires no further differential if classic.

Seizures (atonic/drop attacks):

Syncope (vasovagal, cardiac):

Psychogenic non-epileptic events (PNEE):

Transient ischemic attacks (TIAs):

Periodic paralysis (hypokalemic/hyperkalemic):

Preventive Care and Screening

— Persistent EDS despite adequate sleep

— Unexplained falls or episodes of muscle weakness

— Adolescent with new-onset EDS + rapid weight gain

— Recurrent motor vehicle accidents or near-misses due to sleepiness

— Self-reported measure of sleepiness across 8 situations

— Score >10 suggests excessive sleepiness; >15 is severe

— Useful for screening and monitoring treatment response

— Not diagnostic — must be followed by PSG/MSLT

— Not recommended as screening (poor specificity)

— Useful to help exclude narcolepsy Type 1 (negative test makes Type 1 very unlikely)

— Pandemrix (AS03-adjuvanted) linked to ↑ narcolepsy incidence in Europe

— Current influenza vaccines have no established association

Board pearl: Narcolepsy is often delayed 8–15 years from symptom onset to diagnosis. Maintain high clinical suspicion in young patients with EDS.

No population-level screening exists for narcolepsy

Clinical screening should be prompted by:

Epworth Sleepiness Scale (ESS):

HLA-DQB1*06:02 testing:

H1N1 influenza vaccine association:

Follow-Up and Monitoring

— Assess symptom control: frequency of sleep attacks, cataplexy episodes

— Epworth Sleepiness Scale for objective tracking

— Side effect monitoring for medications

— Modafinil: LFTs if hepatic concerns; ensure adequate contraception (↓ OCP efficacy)

— Sodium oxybate: Na⁺ intake assessment (high sodium content), respiratory status, weight

— Stimulants: HR, BP, weight, signs of dependence/misuse

— Pitolisant: ECG for QTc interval

— Reassess at each visit; state-specific reporting laws apply

— Encourage patients to avoid driving during known periods of high sleepiness

— Screen for depression, anxiety at each visit

— Academic/occupational accommodations under disability protections

— Support groups and patient education resources

Next best step: Counsel all patients on the legal obligation to report narcolepsy diagnosis for driving licensure in states that require physician reporting.

Regular follow-up every 3–6 months once stable:

Medication-specific monitoring:

Driving fitness:

Psychosocial well-being:

Ethical, Legal, and Patient Safety Considerations

— Narcolepsy patients have 3–7× ↑ risk of motor vehicle accidents

— Some jurisdictions mandate physician reporting of conditions impairing driving

— Ethical duty: discuss risk, document counseling, encourage self-restriction until treatment is optimized

— Patients should avoid occupations with high risk of injury from sudden sleep/cataplexy (heavy machinery, commercial driving, piloting)

— Americans with Disabilities Act (ADA): narcolepsy qualifies as a disability → reasonable accommodations (flexible schedule, nap breaks)

— Sodium oxybate — REMS program required; single pharmacy distribution; abuse potential

— Stimulants — Schedule II; prescription monitoring program (PMP) checks

— Avoid stigmatizing patients who require these medications

— Discuss teratogenicity of modafinil in women of childbearing age

— Discuss respiratory depression risk with sodium oxybate, especially with concomitant CNS depressants

Board pearl: Always document driving counseling in the medical record for narcolepsy patients — it is a medicolegal imperative.

Driving safety:

Workplace safety:

Controlled substance considerations:

Informed consent:

High-Yield Associations and Rapid-Fire Facts

Hypocretin (orexin) neurons located in lateral hypothalamus

Narcolepsy Type 1 = autoimmune destruction of orexin neurons → HLA-DQB1*06:02

CSF hypocretin-1 ≤110 pg/mL = diagnostic of Type 1

MSLT criteria: mean sleep latency ≤8 min + ≥2 SOREMPs

SOREMP = REM within 15 minutes of sleep onset

Cataplexy = pathognomonic for Type 1; consciousness preserved

Refreshing short naps = narcolepsy; unrefreshing long naps = idiopathic hypersomnia

Sodium oxybate = only drug treating EDS + cataplexy + sleep consolidation

Modafinil = first-line for EDS; does NOT treat cataplexy

Venlafaxine = commonly used anticataplectic (REM suppression)

Abrupt SNRI/TCA withdrawal → status cataplecticus

Pandemrix vaccine → ↑ narcolepsy (historical association)

Narcolepsy + obesity → orexin deficiency ↓ energy expenditure

Secondary narcolepsy → hypothalamic lesion (tumor, sarcoid, MS) → get MRI

Drug-induced false MSLT: REM-suppressing meds must be stopped ≥2 weeks prior

Board Question Stem Patterns

17M, irresistible sleepiness, refreshing naps, sudden jaw drop when laughing → Narcolepsy Type 1 → PSG + MSLT → start modafinil for EDS + venlafaxine or sodium oxybate for cataplexy

25F, EDS ×6 months, MSLT mean latency 4 min with 3 SOREMPs, no cataplexy → Narcolepsy Type 2 → modafinil

Young adult, EDS, short naps refreshing, CSF hypocretin-1 = 40 pg/mL → Narcolepsy Type 1 confirmed by CSF regardless of MSLT result

14M, new EDS + 15 lb weight gain over 3 months + facial hypotonia → Pediatric narcolepsy Type 1 → CSF hypocretin-1 if MSLT equivocal

Patient on venlafaxine for cataplexy, medication abruptly stopped, now continuous muscle weakness episodes → Status cataplecticus → reinstate venlafaxine

30F with narcolepsy discovers she is pregnant → Discontinue modafinil (teratogenic) → maximize non-pharmacologic measures

Patient with EDS, MSLT normal, prolonged unrefreshing naps, severe sleep inertia → Idiopathic hypersomnia, not narcolepsy

EDS patient with BMI 38, snoring, AHI 35 on PSG → Treat OSA first → if EDS persists after CPAP → reassess for narcolepsy

One-Line Recap

Narcolepsy is a chronic central hypersomnolence disorder caused by hypocretin (orexin) deficiency (Type 1, with pathognomonic cataplexy and CSF hypocretin-1 ≤110 pg/mL) or unknown mechanism (Type 2, no cataplexy), diagnosed via PSG followed by MSLT showing mean sleep latency ≤8 min with ≥2 SOREMPs after excluding insufficient sleep and OSA, managed with modafinil as first-line for EDS plus sodium oxybate (uniquely treating EDS, cataplexy, and disrupted sleep) or REM-suppressing agents (venlafaxine, SSRIs, TCAs) for cataplexy, with critical attention to driving safety counseling, avoidance of abrupt anticataplectic withdrawal (risk of status cataplecticus), modafinil teratogenicity in pregnancy, and MRI brain to exclude secondary hypothalamic pathology in atypical or late-onset presentations.

Previous Item

Next Item

eduo

visual

Nervous System

eduovisual

Products

Exams

Company